Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings in Brief: NeoPath

This article was originally published in The Gray Sheet

Executive Summary

NeoPath: Planning secondary offering of 2.5 mil. shares of common stock. Based on the issue's current NASDAQ trading price of about $20 per share, the offering could net $45 mil. to $50 mil., the firm says. Proceeds are slated to expand manufacturing capacity for the Redmond, Washington-based firm's AutoPap 300 QC automated Pap smear analyzer, approved by FDA in September ("The Gray Sheet" Oct. 9, p. 6), and for working capital. NeoPath, which currently has about 10 mil. shares outstanding, plans to file a registration statement with SEC during December for the offering. The company says it currently has about $27 mil. in cash remaining from a $35 mil. initial public offering of 3.5 mil. shares completed in January ("The Gray Sheet" Dec. 19, 1994, p. 26)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT005162

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel